Concomitant calcium supplementation does not compromise immunosuppressive dosing in kidney transplant recipients
British Journal of Clinical Pharmacology · 31.10.2026
DOI: 10.1002/bcp.70905 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 31.10.2026. Verfasst von Ludvig Husby Aftret und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Oslo, Oslo, Norway. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Oslo University Hospital, Rikshospitalet, University of Oslo, Universitetet i Oslo.
Abstract (Originalsprache)
Background
Polypharmacy following kidney transplantation entails a risk of both drug–drug interactions (DDIs) and reduced patient adherence. Co‐administration of calcium supplementation and mycophenolate mofetil (MMF) has previously been shown to influence pharmacokinetics (PK) of MMF. In current DDI databases, there is a recommendation for 2‐ to 3‐h time‐shifted administration. Whether a similar interaction potentially exists for tacrolimus has not been evaluated. We aimed to investigate the potential PK DDI between co‐administrated calcium/vitamin D supplementation and the immunosuppressive drugs MMF and tacrolimus, using volumetric absorptive microsampling (VAMS).
Methods
Twenty‐five kidney transplant recipients on stable MMF, tacrolimus and prednisolone treatment provided two 12‐h PK investigations of simultaneous assessment of both mycophenolic acid (MPA) and tacrolimus concentrations. One PK investigation with and one without concomitant treatment with a calcium/vitamin D supplement. Capillary blood samples using VAMS were utilized to obtain samples in a patient friendly manner. Clinically relevant interactions were assessed by the with/without ratio of AUC 0–12 and C max in accordance with EMA bioequivalence guidelines.
Results
The MPA AUC 0–12 ratio was 0.94 (90% confidence interval [CI], 0.83–1.07) and the C max ratio was 0.79 (90% CI, 0.65–0.97). For tacrolimus, the AUC 0–12 and C max ratios were 1.00 (90% CI, 0.92–1.09) and 0.96 (90% CI, 0.87–1.07), respectively.
Conclusion
In kidney transplant recipients there is no clinically relevant PK DDI caused by concomitant administration of calcium/vitamin D supplementation with MMF and tacrolimus. Based on these observations, recommendation of time‐shifted administration of calcium supplements and immunosuppressive drugs seems unnecessary.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, University of Oslo, Oslo, Norway.
- Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Department of Nephrology, Drammen Hospital, Drammen, Norway.
- Department of Clinical Pharmacology, Oslo University Hospital, Oslo, Norway.
ORCID-Profile: Ludvig Husby Aftret, Karsten Midtvedt, Kristian Heldal, Nils Tore Vethe, Ida Robertsen, Anders Åsberg, Dag Olav Dahle
Förderung
- Oslo University Hospital, Rikshospitalet
- University of Oslo
- Universitetet i Oslo
Zitieren
APA
Aftret, L. H., Ellingsen, A. Ø., Midtvedt, K., Heldal, K., Reier-Nilsen, M., Vethe, N. T., Robertsen, I., Åsberg, A., & Dahle, D. O. (2026). Concomitant calcium supplementation does not compromise immunosuppressive dosing in kidney transplant recipients. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70905
Vancouver
Aftret LH, Ellingsen AØ, Midtvedt K, Heldal K, Reier-Nilsen M, Vethe NT, et al. Concomitant calcium supplementation does not compromise immunosuppressive dosing in kidney transplant recipients. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70905
BibTeX
@article{Aftret2026,
author = {Aftret, Ludvig Husby and Ellingsen, Andreas Ørås and Midtvedt, Karsten and Heldal, Kristian and Reier-Nilsen, Morten and Vethe, Nils Tore and Robertsen, Ida and Åsberg, Anders and Dahle, Dag Olav},
title = {Concomitant calcium supplementation does not compromise immunosuppressive dosing in kidney transplant recipients},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70905}
}
EUVIMED